Levy Arkene, Leynes Carolina, Baig Mirza, Chew Sue Anne
Department of Pharmacology, College of Medical Sciences, Nova Southeastern University, 3200 South University Drive, Davie, FL, 33328, USA.
Department Health and Biomedical Sciences, University of Texas Rio Grande Valley, One West University Boulevard, Brownsville, TX, 78520, USA.
ChemMedChem. 2019 Nov 6;14(21):1810-1827. doi: 10.1002/cmdc.201900450. Epub 2019 Oct 29.
More than 70 % of women with ovarian cancer are diagnosed with advanced-stage disease, which is initially treated with cytoreductive surgery, and combination chemotherapy with platinum-based compounds. Most patients initially respond to platinum-based therapy, but eventually up to 80 % of this responsive cohort becomes refractory due to the development of platinum resistance. This review discusses current and potential therapeutic approaches that exploit biomaterial-based applications to combat platinum resistance either by enhancing the delivery of platinum-based drugs or prodrugs, delivering other toxic non-platinum-based bioactive factors (by themselves or in combination with platinum-based drugs) or by delivering other bioactive factors that re-sensitize resistant ovarian cancer cells to these drugs. The types of materials that are used, the bioactive factors applied (i.e., drug or gene delivery), and the specific agents that are employed to target these types of cancer cells are discussed. We conclude that the unique attributes of biomaterial-based applications can be further explored toward overcoming platinum-resistant ovarian cancer as monotherapy, or in combination with other treatment strategies.
超过70%的卵巢癌女性被诊断为晚期疾病，最初采用细胞减灭术以及铂类化合物联合化疗进行治疗。大多数患者最初对铂类疗法有反应，但最终由于铂耐药的发展，该反应性队列中高达80%的患者会变得难治。本综述讨论了当前和潜在的治疗方法，这些方法利用基于生物材料的应用来对抗铂耐药，方法包括增强铂类药物或前药的递送、递送其他有毒的非铂类生物活性因子（单独或与铂类药物联合），或递送其他能使耐药卵巢癌细胞对这些药物重新敏感的生物活性因子。文中讨论了所使用材料的类型、应用的生物活性因子（即药物或基因递送）以及用于靶向这类癌细胞的特定药物。我们得出结论，基于生物材料的应用的独特属性可进一步探索，以作为单一疗法或与其他治疗策略联合来克服铂耐药性卵巢癌。
